• OUTLOOK ARENA
  • VIEWS ON NEWS
  • JANUARY 31, 2001

Dr. Reddy's 3QFY01: The Cheminor muscle

Dr. Reddy’s has reported a 45% growth in net profits, in the third quarter of the current year on the back of a 77% topline growth. However, these numbers are not comparable as the current year’s third quarter numbers include those of Cheminor Laboratories. Infact, on a consolidated basis the company’s topline has grown by 26% plus while the net profit’s have grown by 14% plus. The margin growth has been relatively slower primarily because of the increase of the contribution from bulk drugs. (Bulk drugs contribute around 51% of the combined company’s turnover.)

(Rs m) 3QFY00 3QFY01 Change
Sales 1,210 2,144 77.2%
Other Income 3 84 2706.7%
Expenditure 908 1,687 85.9%
Operating Profit (EBDIT) 303 457 50.9%
Operating Profit Margin (%) 25.0% 21.3%  
Interest 30 76  
Depreciation 44 102 130.5%
Profit before Tax 231 362 57.0%
Other Adjustments   -  
Tax 10 43 326.0%
Profit after Tax/(Loss) 221 320 44.8%
Net profit margin (%) 18.2% 14.9%  
Earnings per share* 27.96 40.47  

While the bulk actives business grew by 27% the generic sales in developed market took off in the third quarter of December 31, 2000. The finished dosages at Rs. 998 m contributed to 46% of revenues. Another significant development in the third quarter was the fact that the company’s anti-cancer compound DRF 1042 entered Phase I of clinical trials.

During the quarter all the company’s main brands Omez (anti–ulcer), Nise (anti–pain), Enam (cardiovascular) and Stamlo registered growth rates much higher than the rate of growth of overall pharmaceutical formulations. While the industry grew by 11%, Omez grew by 20%. Nise registered a growth of 17%, while Enam and Stamlo (including Stamlo Beta) grew by 29% and 26% respectively. The company also launched eight new brands, which catered to therapeutic areas such as anti–arthritis, anti–diabetes and cholesterol reducers.

The stock quotes at Rs 1,300 currently which implies an earnings multiple of 32 times 3QFY01 earnings.

Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

Equitymaster Agora Research Private Limited (Research Analyst)
103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407